BSE · 540694
ANG Lifesciences India Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹14 Cr with net profit ₹-3 Cr — a -24.5% net margin, versus 4.82% the period before.
Shareholding
As of 2026-09-30
- Promoter70.6%
- Public29.4%
5,666 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.82× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #79 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,51,075 Cr | 36.65 | 5.05 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,30,972 Cr | 97.74 | 21.57 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,18,693 Cr | 26.12 | 4.27 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,15,267 Cr | 41.17 | 2.96 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,12,442 Cr | 36.21 | 3.18 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,09,044 Cr | 46.73 | 6.23 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,04,903 Cr | 25.85 | 2.67 | 10.13% | 10.88% |
| Lupin Limited | ₹90,558 Cr | 16.07 | 3.76 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹74,507 Cr | 36.78 | 6.65 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹61,146 Cr | 28.2 | 4.11 | 13.91% | 13.23% |
| ANG Lifesciences India Limited(this company) | ₹54 Cr | — | 1.12 | -20.96% | -15.94% |
AI analysis
AI-generated · google/gemini-2.5-flashANG Lifesciences India Limited has a market capitalization of Rs 42 Cr. The company reported a revenue of Rs 94.87 Cr and a profit margin of -11.94%. Its book value per share is Rs 40.5. The promoter holding stands at 70.603%, with 44.88% of promoter shares pledged.
Positives
- +Promoter holding is 70.603% as of March 31, 2026, indicating significant control by the promoters.
Negatives
- −The company has negative profitability, as evidenced by a profit margin of -11.94%.
- −Return on equity (ROE) is negative at -20.96%, indicating losses relative to shareholder equity.
- −Return on capital employed (ROCE) is negative at -3.8346%, showing inefficient use of capital.
- −The debt-to-equity ratio is 1.11, suggesting a relatively high level of debt.
- −A significant portion (44.88%) of promoter shares are pledged as of March 31, 2026.
- −The company is under Exchange Surveillance Measure (ESM 1).
Financial Performance
For the fiscal year ending March 2025, ANG Lifesciences India Limited reported a revenue of Rs 94.8662 Cr. The net profit for the same period was -Rs 12.4133 Cr, resulting in an EPS of -Rs 9.42. The company's profit margin was -11.94%.
Profitability & Returns
The company's return on equity (ROE) was -20.96%, and its return on capital employed (ROCE) was -3.8346%. These figures indicate negative returns generated from shareholder funds and total capital employed, respectively. The company reported a profit margin of -11.94%.
Balance Sheet
ANG Lifesciences India Limited has a book value per share of Rs 40.5. The debt-to-equity ratio stands at 1.11, indicating a reliance on debt financing. No dividend yield was reported for the company.
Ownership & Pledges
As of March 31, 2026, the promoter holding in ANG Lifesciences India Limited was 70.603%. The public held 29.397% of the shares. There were no reported holdings by DII or FII. A significant portion of promoter shares, 44.88%, was pledged.
Regulatory & Surveillance
ANG Lifesciences India Limited is currently under the Exchange Surveillance Measure (ESM) framework, specifically 'ESM 1', indicating increased monitoring by regulatory bodies.
Data as of — price: 2026-11-14 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to ANG Lifesciences India Limitedshare price & fundamentals